(Q46048883)

English

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

2

object named as

Paul Emery

0 references

Ronald van Vollenhoven

4

object named as

Ronald F van Vollenhoven

0 references

1

object named as

Josef S Smolen

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Arthur Kavanaugh

11

object named as

Arthur Kavanaugh

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

6

object named as

Patrick Durez

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

author name string

Roy Fleischmann

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Benoît Guérette

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Hartmut Kupper

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Laura Redden

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Vipin Arora

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

language of work or name

0 references

publication date

26 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

383

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

9914

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

321-332

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Epidemiology of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The definition and measurement of disease modification in inflammatory rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961751-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)61751-1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/24168956

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46048883&oldid=2115041365"